阿替利珠单克隆抗体联合贝伐珠单克隆抗体治疗初始临界可切除中晚期肝癌的临床疗效  

Clinical efficacy of Atezolizumab and Bevacizumab in the treatment of initially borderline resectable advanced liver cancer

作　　者：姚博文[1] 向俊西[1] 郑鑫[1] 孙昊[1] 杨威[1] 张月浪[2] 叶峰[3] 赵东利[4] 姚英民[1] 刘青光[1] 郭成[1] Yao Bowen;Xiang Junxi;Zheng Xin;Sun Hao;Yang Wei;Zhang Yuelang;Ye Feng;Zhao Dongli;Yao Yingmin;Liu Qingguang;Guo Cheng(Department of Hepatobiliary Surgery,the First Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710061,China;Department of Medical Imaging,the First Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710061,China;Department of Infectious Disease,the First Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710061,China;Oncology Department,the First Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710061,China)

机构地区：[1]西安交通大学第一附属医院肝胆外科,西安710061 [2]西安交通大学第一附属医院影像科,西安710061 [3]西安交通大学第一附属医院感染科,西安710061 [4]西安交通大学第一附属医院肿瘤放疗科,西安710061

出　　处：《中华消化外科杂志》2022年第2期303-306,共4页Chinese Journal of Digestive Surgery

基　　金：陕西省重点研发计划(2021SF-225)。

摘　　要：转化治疗已成为临界可切除或不可切除肝癌治疗的核心, 为更多晚期肝癌患者提供可切除机会。根据临床指南关于肝癌一线治疗方案推荐, 笔者总结并分析1例初始临界可切除中晚期肝癌患者行阿替利珠单克隆抗体联合贝伐珠单克隆抗体(T+A方案)转化治疗后, 成功行肝段切除术, 且术后9个月随访未见肿瘤复发。该例患者术后病理学检查为肝细胞-胆管细胞混合型肝癌。这提示T+A方案在混合型肝癌转化治疗中具有重要价值。Conversion therapy has become the core in the treatment of borderline resectable or unresectable liver cancer,which provides resectable opportunities for more advanced liver cancer patients.In accordance with the first-choice treatment regimen recommended by the guidelines,the authors reported a successful case of Atezolizumab and Bevacizumab(T+A regimen)conversion therapy.The patient with initially borderline resectable advanced liver cancer was performed liver segment resection sucessfully after conversion therapy,and non-tumor recurrence was observed at postoperative 9 months.Postoperative pathological examination showed combined hepatocellular-cholangiocarcinoma,which also indicated the important value of T+A regimen in the conversion therapy of combined hepatocellular-cholangiocarcinoma.

关 键 词：肝肿瘤 转化治疗 免疫治疗 肝切除 多学科 

分 类 号：R735.7[医药卫生—肿瘤]